SCHEDULE: Great Point Partners Reduces Unicycive Therapeutics Stake Below 5%

Great Point Partners, along with Dr. Jeffrey R. Jay and Ms. Lillian Nordahl, has reduced their beneficial ownership in Unicycive Therapeutics, Inc. to 4.51%.

Summary

• Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl have filed an Amendment No. 4 to Schedule 13G for Unicycive Therapeutics, Inc.
• The reporting persons collectively beneficially own 796,558 shares of Unicycive Therapeutics' common stock.
• This ownership represents 4.51% of the company's outstanding common stock, based on 17,661,698 shares outstanding as reported in the Issuer's Form 10-Q filed on August 14, 2025.
• The reporting persons share both voting and dispositive power over all 796,558 shares.
• The event requiring this filing occurred on September 30, 2025, indicating a reduction in their stake below the 5% threshold.
• The filing certifies that the securities were not acquired or held for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to a significant institutional investor reducing its stake below the 5% threshold, which can be interpreted as a decrease in confidence or a strategic move away from the company.

Negatives

• A significant institutional investor, Great Point Partners, along with its principals, has reduced its stake in Unicycive Therapeutics, Inc. below the 5% beneficial ownership threshold, which could be interpreted as a decrease in confidence or a strategic divestment.

Risks

• The reduction in beneficial ownership by a notable institutional investor may lead to negative market perception regarding the company's future prospects or current valuation.
• A decrease in institutional holdings can sometimes precede further selling pressure or reduced liquidity for the stock.

Future Outlook

NA

Management Comments

• Dr. Jeffrey R. Jay, M.D., as Senior Managing Member of Great Point Partners, LLC, certified that, to the best of his knowledge and belief, the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

This filing reflects a change in institutional investment posture for Unicycive Therapeutics, a common occurrence in the biotechnology or pharmaceutical sector where investment firms frequently adjust their holdings based on clinical trial progress, regulatory milestones, or market conditions. Such adjustments are part of the dynamic nature of investing in growth-oriented companies.

Stakeholder Impact

• Shareholders may perceive a reduction in institutional confidence, potentially influencing their investment decisions.
• The company's stock price could experience downward pressure if the market interprets the reduction in ownership negatively.

Key Dates

Recommendation

The reduction of a significant institutional stake below the 5% threshold by Great Point Partners is a notable event. While not an outright 'sell' signal without further context on the investor's rationale or the company's fundamentals, it suggests a potential decrease in institutional confidence. Investors should 'hold' and monitor for further developments, including any subsequent filings or company announcements that might explain this divestment, before making aggressive buy or sell decisions.

Keywords

Unicycive Therapeutics, Great Point Partners, Schedule 13G, Beneficial Ownership, Institutional Ownership, Equity Stake, Investment Management